Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities

Nature

Volumn 531, Issue 7592, 2016, Pages 110-113

  Kerr, Emma M ^a   Gaude, Edoardo ^a   Turrell, Frances K ^a   Frezza, Christian ^a   Martins, Carla P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; K RAS PROTEIN; GLUCOSE;

ALLELE; CANCER; CELLS AND CELL COMPONENTS; DETOXIFICATION; HETEROZYGOSITY; METABOLITE; MUTATION; PHENOTYPE; PROTEIN; TUMOR;

ALLELE; ANIMAL CELL; ARTICLE; CITRIC ACID CYCLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DETOXIFICATION; EMBRYO; FIBROBLAST; GENE MUTATION; GENOTYPE; HUMAN; IN VIVO STUDY; LUNG CANCER CELL LINE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; WILD TYPE; ANIMAL; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION; DISEASE COURSE; DRUG EFFECTS; FEMALE; GENETICS; GLYCOLYSIS; LUNG NEOPLASMS; MALE; METABOLISM; MUTATION; ONCOGENE RAS; OXIDATION REDUCTION REACTION; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

MURINAE; MUS;

ALLELES; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CITRIC ACID CYCLE; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; FEMALE; FIBROBLASTS; GENES, RAS; GENOTYPE; GLUCOSE; GLUTATHIONE; GLYCOLYSIS; LUNG NEOPLASMS; MALE; MICE; MUTATION; OXIDATION-REDUCTION; PHENOTYPE; PROGNOSIS;

EID: 84960154307     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature16967     Document Type: Article

References (29)

1. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014).
2. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
3. Vicent, S. et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br. J. Cancer 90, 1047-1052 (2004).
4. Guerra, C. et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111-120 (2003).
5. Jackson, E. L. et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280-10288 (2005).
6. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
7. Junttila, M. R. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468, 567-571 (2010).
8. Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nature Rev. Cancer 11, 761-774 (2011).
9. Sarkisian, C. J. et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nature Cell Biol. 9, 493-505 (2007).
10. Modrek, B. et al. Oncogenic activating mutations are associated with local copy gain. Mol. Cancer Res. 7, 1244-1252 (2009).
11. Tuveson, D. A. et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375-387 (2004).
12. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genet. 29, 418-425 (2001).
13. Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670 (2012).
14. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
15. G12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res. 22, 399-412 (2012).
16. Baracca, A. et al. Mitochondrial complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells. Biochim. Biophys. Acta 1797, 314-323 (2010).
17. Gaglio, D. et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol. Syst. Biol. 7, 523 (2011).
18. Son, J. et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101-105 (2013).
19. Kaplon, J. et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 498, 109-112 (2013).
20. DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106-109 (2011).
21. Gorrini, C., Harris, I. S. & Mak, T. W. Modulation of oxidative stress as an anticancer strategy. Nature Rev. Drug Discov. 12, 931-947 (2013).
22. Bryant, K. L., Mancias, J. D., Kimmelman, A. C. & Der, C. J. KRAS: feeding pancreatic cancer proliferation. Trends Biochem. Sci. 39, 91-100 (2014).
23. Griffith, O. W. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J. Biol. Chem. 257, 13704-13712 (1982).
24. To, M. D., Rosario, R. D., Westcott, P. M., Banta, K. L. & Balmain, A. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis. Oncogene 32, 4028-4033 (2013).
25. Zhang, Z. et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nature Genet. 29, 25-33 (2001).
26. Wagner, P. L. et al. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. Lung Cancer 74, 118-123 (2011).
27. Johnson, L. et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11, 2468-2481 (1997).
28. Christophorou, M. A. et al. Temporal dissection of p53 function in vitro and in vivo. Nature Genet. 37, 718-726 (2005).
29. Martins, C. P., Brown-Swigart, L. & Evan, G. I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334 (2006).